Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. more
Time Frame | HOWL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.19% | -3.35% | -2.97% |
1-Month Return | -5.99% | -3.49% | -0.66% |
3-Month Return | -34.58% | -12.6% | 2.71% |
6-Month Return | -41.64% | -6.91% | 7.21% |
1-Year Return | -47.84% | 1.19% | 23.04% |
3-Year Return | -86.56% | -0.21% | 28.43% |
5-Year Return | -90.25% | 33.09% | 82.88% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 4.15M | 16.40M | 19.94M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":20.8,"profit":true},{"date":"2022-12-31","value":82.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 463.00K | 777.00K | 735.00K | 2.51M | 38.91M | [{"date":"2019-12-31","value":1.19,"profit":true},{"date":"2020-12-31","value":2,"profit":true},{"date":"2021-12-31","value":1.89,"profit":true},{"date":"2022-12-31","value":6.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (463.00K) | (777.00K) | (735.00K) | 16.40M | (18.96M) | [{"date":"2019-12-31","value":-2.82,"profit":false},{"date":"2020-12-31","value":-4.74,"profit":false},{"date":"2021-12-31","value":-4.48,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-115.62,"profit":false}] |
Gross Margin | - | - | (17.72%) | 100.00% | (95.09%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-17.72,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-95.09,"profit":false}] |
Operating Expenses | 9.94M | 22.40M | 50.09M | 72.46M | 60.45M | [{"date":"2019-12-31","value":13.71,"profit":true},{"date":"2020-12-31","value":30.92,"profit":true},{"date":"2021-12-31","value":69.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.42,"profit":true}] |
Operating Income | (9.94M) | (22.40M) | (50.09M) | (56.06M) | (40.50M) | [{"date":"2019-12-31","value":-993600000,"profit":false},{"date":"2020-12-31","value":-2240400000,"profit":false},{"date":"2021-12-31","value":-5008700000,"profit":false},{"date":"2022-12-31","value":-5605600000,"profit":false},{"date":"2023-12-31","value":-4050300000,"profit":false}] |
Total Non-Operating Income/Expense | (684.00K) | 7.46M | 208.00K | 4.15M | 7.63M | [{"date":"2019-12-31","value":-8.97,"profit":false},{"date":"2020-12-31","value":97.89,"profit":true},{"date":"2021-12-31","value":2.73,"profit":true},{"date":"2022-12-31","value":54.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (10.25M) | (15.04M) | (49.98M) | (53.81M) | (37.37M) | [{"date":"2019-12-31","value":-1024800000,"profit":false},{"date":"2020-12-31","value":-1504000000,"profit":false},{"date":"2021-12-31","value":-4998300000,"profit":false},{"date":"2022-12-31","value":-5381000000,"profit":false},{"date":"2023-12-31","value":-3736800000,"profit":false}] |
Income Taxes | 742.00K | (101.00K) | (216.00K) | (2.25M) | 1.60M | [{"date":"2019-12-31","value":46.49,"profit":true},{"date":"2020-12-31","value":-6.33,"profit":false},{"date":"2021-12-31","value":-13.53,"profit":false},{"date":"2022-12-31","value":-140.72,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (10.99M) | (14.94M) | (49.77M) | (51.56M) | (38.96M) | [{"date":"2019-12-31","value":-1099000000,"profit":false},{"date":"2020-12-31","value":-1493900000,"profit":false},{"date":"2021-12-31","value":-4976700000,"profit":false},{"date":"2022-12-31","value":-5156400000,"profit":false},{"date":"2023-12-31","value":-3896410500,"profit":false}] |
Income From Continuous Operations | (10.25M) | (15.04M) | (49.98M) | (53.81M) | (37.30M) | [{"date":"2019-12-31","value":-1024800000,"profit":false},{"date":"2020-12-31","value":-1504000000,"profit":false},{"date":"2021-12-31","value":-4998300000,"profit":false},{"date":"2022-12-31","value":-5381000000,"profit":false},{"date":"2023-12-31","value":-3729500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.99M) | (14.94M) | (49.77M) | (51.56M) | (37.37M) | [{"date":"2019-12-31","value":-1099000000,"profit":false},{"date":"2020-12-31","value":-1493900000,"profit":false},{"date":"2021-12-31","value":-4976700000,"profit":false},{"date":"2022-12-31","value":-5156400000,"profit":false},{"date":"2023-12-31","value":-3736800000,"profit":false}] |
EPS (Diluted) | - | - | (88.35) | (1.88) | (1.04) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-8835,"profit":false},{"date":"2022-12-31","value":-188,"profit":false},{"date":"2023-12-31","value":-104,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
HOWL | |
---|---|
Cash Ratio | 9.95 |
Current Ratio | 10.10 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HOWL | |
---|---|
ROA (LTM) | -26.16% |
ROE (LTM) | -61.56% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HOWL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.36 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.64 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HOWL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 19.48 |
P/B | 0.73 |
Price/FCF | NM |
EV/R | 0.67 |
EV/Ebitda | 0.57 |
Werewolf Therapeutics Inc (HOWL) share price today is $1.57
Yes, Indians can buy shares of Werewolf Therapeutics Inc (HOWL) on Vested. To buy Werewolf Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HOWL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Werewolf Therapeutics Inc (HOWL) via the Vested app. You can start investing in Werewolf Therapeutics Inc (HOWL) with a minimum investment of $1.
You can invest in shares of Werewolf Therapeutics Inc (HOWL) via Vested in three simple steps:
The 52-week high price of Werewolf Therapeutics Inc (HOWL) is $8.19. The 52-week low price of Werewolf Therapeutics Inc (HOWL) is $1.38.
The price-to-earnings (P/E) ratio of Werewolf Therapeutics Inc (HOWL) is
The price-to-book (P/B) ratio of Werewolf Therapeutics Inc (HOWL) is 0.73
The dividend yield of Werewolf Therapeutics Inc (HOWL) is 0.00%
The market capitalization of Werewolf Therapeutics Inc (HOWL) is $65.95M
The stock symbol (or ticker) of Werewolf Therapeutics Inc is HOWL